Ivonescimab plus enfortumab vedotin for advanced bladder cancer
Treatments studied
Part of Cancer clinical trials.
This study compares two drug combinations for advanced bladder cancer that has spread or cannot be removed with surgery. The drugs aim to help the immune system fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are physically active and able to care for yourself (ECOG 0-1).
- You have advanced bladder, renal pelvis, ureter, or urethral cancer that is transitional cell carcinoma and cannot be surgically removed, with at least half of the tumor being urothelial (transitional cell) cancer.
- You have not received any prior systemic (whole-body) treatment for this cancer.
- You have at least one measurable tumor outside the brain.
- You have adequate organ function.
- You do not have tumors with small cell or neuroendocrine components, severe neuropathy, high bleeding risk, or recent major bowel issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-drug combination (pembrolizumab and enfortumab vedotin) followed by maintenance pembrolizumab for people with advanced bladder cancer that has not been treated before. The goal is to see if this approach helps control the cancer for longer.
This trial adds an investigational drug, GB-4362, to a standard combination of two medicines (enfortumab vedotin and pembrolizumab) for advanced bladder cancer. The study wants to see if adding this drug is safe and helps treat the cancer better.
This Phase 1 study tests whether cabozantinib combined with enfortumab vedotin can help people with advanced urothelial (bladder) cancer that has already been treated with immunotherapy (PD-1/PD-L1) and usually chemotherapy. It aims to find a safer dose and see if the combo can shrink tumors or control the disease.
This Phase 1/2 trial tests whether combining sacituzumab govitecan with enfortumab vedotin (and in one group, pembrolizumab) can shrink or control metastatic urothelial (bladder/urinary tract) cancer. It’s mainly for people whose cancer has grown despite prior treatment.
This study tests a new drug called enfortumab vedotin for people whose advanced urothelial cancer (bladder or urinary tract cancer) has not responded to prior immunotherapy (checkpoint inhibitors) and platinum chemotherapy. The goal is to see how safe and effective this treatment is for Indian adults.
This trial tests a combination of three drugs (N-803, pembrolizumab, and enfortumab vedotin) for advanced bladder cancer that has not been treated with systemic therapy. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
Hear when a new Metastatic Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.